If you have osteoporosis and a dentist has told you that you are "not a candidate" for dental implants, you deserve a fuller explanation. Osteoporosis on its own is not a barrier to implant treatment, and published survival rates in osteoporotic patients sit within a few percentage points of everyone else. The real conversation is about medication — specifically bisphosphonates and denosumab — plus bone quality, healing time, and how carefully your surgical team coordinates with the physician who manages your bones. This guide walks through what actually changes when you have low bone density, what the research shows, and what to ask before you commit to anything in Las Vegas.
Osteoporosis is a systemic disease, but it does not attack every bone equally. It preferentially thins trabecular bone — the spongy, honeycomb-like interior found in abundance in the vertebrae, the femoral neck, and the wrist. That is why hip and spine fractures dominate the clinical picture and why a DEXA scan measures those exact sites.
The jaws are built differently. The mandible in particular is dense cortical bone with a comparatively thin trabecular core, and it is under constant functional loading from chewing. Cortical bone loses density more slowly than trabecular bone. Multiple studies that compared DEXA T-scores to jawbone measurements have found only a weak-to-moderate correlation — a woman can have a spine T-score of -3.0 and still present with a perfectly serviceable posterior mandible.
This is the single most important thing patients with osteoporosis misunderstand. Your skeletal diagnosis describes your fracture risk. It does not, by itself, describe the bone your surgeon will actually be drilling into. That has to be measured directly.
Bring your most recent DEXA report to your implant consultation. Not the summary sentence your doctor read to you — the actual printout with the T-scores and the date. It tells your surgeon far more than "I have osteoporosis" does.
Systematic reviews published over the past decade have consistently found that implants placed in patients with osteoporosis survive at rates broadly comparable to those in patients with normal bone density. Reported survival typically lands around 95–97% at five years for osteoporotic patients versus roughly 97–98% for controls. The gap is real but small, and it is dwarfed by the effect of smoking, uncontrolled diabetes, or untreated periodontal disease.
Where the literature does show a consistent difference is in marginal bone loss — the small amount of crestal bone that recedes around the implant collar over time. Osteoporotic patients tend to show modestly greater marginal bone loss, often on the order of a tenth to a few tenths of a millimeter more over several years. That is clinically meaningful for maintenance planning, but it is not the same thing as failure.
| Factor | Typical effect on implant outcome | Manageable? |
|---|---|---|
| Osteoporosis (diagnosis alone) | Small reduction in survival; slightly more marginal bone loss | Yes — protocol adjustments |
| Oral bisphosphonate < 4 years | Very low MRONJ risk; generally proceed normally | Yes |
| Oral bisphosphonate > 4 years | Elevated MRONJ risk; warrants medical consultation | Usually |
| Denosumab (Prolia) | Timing-sensitive; never stop abruptly | Yes — schedule around dosing |
| IV antiresorptives for cancer | Substantially higher MRONJ risk | Often a contraindication |
| Long-term corticosteroids | Compounds risk with any antiresorptive | Requires careful planning |
| Current smoking | Roughly doubles failure risk — larger effect than osteoporosis | Yes — cessation helps |
Bisphosphonates work by suppressing osteoclasts, the cells that break down bone. Less breakdown means denser bone and fewer fractures — an unambiguous win for hip and spine. The trade-off is that bone remodeling slows everywhere, including in the jaw, where remodeling is unusually fast because of the constant mechanical demands of chewing.
Common oral bisphosphonates prescribed across Nevada include alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva). Zoledronic acid (Reclast) is given intravenously once a year for osteoporosis. All of them accumulate in bone and persist for years after the last dose.
Medication-related osteonecrosis of the jaw is exposed, non-healing bone following a dental procedure. It is the complication everyone has heard of and almost nobody has seen. For patients on standard oral osteoporosis doses, the risk after invasive dental surgery is commonly reported in the range of 0.02% to 0.1% — somewhere between one in a thousand and one in five thousand. For patients on high-dose intravenous antiresorptives for metastatic cancer, the reported risk is orders of magnitude higher, often quoted at 1% to 10%.
Those two populations get conflated constantly, including by well-meaning dentists. If you take a weekly Fosamax tablet for postmenopausal osteoporosis, you are not in the high-risk group. If you receive monthly zoledronic acid for bone metastases, you are, and implants are usually deferred.
You may have read that you should stop your bisphosphonate for two months before implant surgery and until the implant integrates. This concept — the "drug holiday" — appears in guidance from the American Association of Oral and Maxillofacial Surgeons for patients on oral bisphosphonates beyond roughly four years, or for shorter durations when corticosteroids or other risk factors are present.
It is worth knowing that the evidence base here is thin. Bisphosphonates have a skeletal half-life measured in years, so a two-month pause does not meaningfully clear the drug from your jaw. Other professional bodies have been openly skeptical that the practice changes outcomes. Meanwhile, stopping treatment carries a genuine, quantifiable fracture cost.
The defensible position is this: the decision is made jointly by your implant surgeon and the physician managing your osteoporosis, weighing your fracture risk against your MRONJ risk. Do not stop a prescribed medication because a dental office suggested it, and be wary of any surgeon who tells you to discontinue treatment without contacting your physician first.
Denosumab (Prolia) is a monoclonal antibody given by injection every six months. Unlike bisphosphonates, it does not bind to bone mineral, and its effects reverse relatively quickly — the half-life is roughly a month, and bone turnover markers rebound within months of a missed dose.
That reversibility cuts both ways. It means surgery can often be scheduled in the window when drug effect is lowest, typically toward the end of the six-month interval and before the next injection. It also means that stopping denosumab is genuinely dangerous: discontinuation without transitioning to another agent has been associated with rapid bone loss and a spike in multiple vertebral fractures. Nobody should ever stop Prolia to accommodate dental work. Timing around it is the correct strategy.
Romosozumab (Evenity) and teriparatide (Forteo) work differently. Teriparatide is anabolic — it builds bone rather than suppressing resorption — and some small studies have suggested it may actually support healing. These are less common but worth disclosing.
Implant surgeons classify jawbone using the Lekholm and Zarb scale, Types I through IV. Type I is dense cortical bone; Type IV is thin cortex surrounding sparse, soft trabecular bone. The posterior maxilla — the upper back jaw — is the most common location for Type IV bone and the most common site of implant difficulty, in osteoporotic and non-osteoporotic patients alike.
A surgeon who recognizes soft bone on a CBCT scan will typically adapt in several ways:
Ask your surgeon directly which of these they plan to use. A specific answer signals someone who has treated your situation before. A vague reassurance does not.
Patients routinely arrive at consultations having merged two unrelated concepts. Osteoporosis is reduced bone density throughout the skeleton. Alveolar bone loss is reduced bone volume in the jaw, caused mainly by tooth extraction, periodontal disease, or long-term denture wear. You can have either without the other.
This distinction determines whether you need grafting. A CBCT scan measures the actual height and width of bone at each planned implant site, and that measurement — not your T-score — drives the decision. For a deeper walkthrough of volume loss and reconstruction options, see our guide on bone loss and dental implants.
Clark County has one of the fastest-growing older populations in the western United States. Retirement communities like Sun City Summerlin, Sun City Anthem in Henderson, and Sun City Aliante in North Las Vegas concentrate exactly the demographic in which osteoporosis is most prevalent — postmenopausal women over 65 account for the large majority of diagnoses nationally.
Two local wrinkles are worth flagging. First, vitamin D deficiency is more common in Las Vegas than the 300-plus days of sunshine would suggest. Summer heat pushes people indoors during peak UVB hours, sun protection is near-universal, and older adults synthesize vitamin D from sunlight far less efficiently than younger ones. Deficiency is common enough here that a serum 25(OH)D test is a reasonable pre-surgical request. Adequate vitamin D supports the bone healing that osseointegration depends on.
Second, many Las Vegas residents are relative newcomers whose osteoporosis is managed by a physician in another state, or not actively managed at all. Implant planning stalls when nobody can produce a current medication list or a DEXA report. Sorting that out before your consultation saves weeks.
| Item | Typical Las Vegas range | Notes |
|---|---|---|
| CBCT 3D scan | $150 – $400 | Often bundled into consultation |
| Single implant (fixture only) | $1,800 – $2,800 | Excludes abutment and crown |
| Single implant, abutment + crown | $3,000 – $5,000 | All-in per tooth |
| Socket preservation graft | $400 – $1,200 | At time of extraction |
| Sinus lift | $1,500 – $3,000 | Common in posterior maxilla |
| Full arch (All-on-4 style) | $20,000 – $30,000 | Per arch, varies widely |
Osteoporosis itself does not usually add a line item. What adds cost is the workup it justifies — additional imaging, a medical consultation letter, and occasionally grafting. Budget a few hundred dollars for diligence and consider it money well spent.
Here is how a well-run case typically unfolds for a Las Vegas patient on long-term alendronate:
Five to eight months from consultation to final crown is a normal, healthy timeline here. Anyone promising a full-arch reconstruction in a single visit to a patient with severe osteoporosis and four years of bisphosphonate history is optimizing for their schedule, not your outcome.
Some situations genuinely warrant delaying or reconsidering implants:
Even most of these are timing problems rather than permanent exclusions. A surgeon who says "not now, and here is what would need to change" is giving you better care than one who either refuses outright or waves the concern away.
Yes. Osteoporosis by itself is not a contraindication to dental implants. Published implant survival rates in patients with osteoporosis are generally in the 95–97% range, only slightly below the 97–98% seen in patients with normal bone density. The jaw is largely cortical bone and behaves differently from the spine and hip, where osteoporosis does the most damage. What matters more is which medications you take and how your surgeon adjusts the surgical protocol.
Never stop either drug on your own. For oral bisphosphonates such as Fosamax taken longer than about four years, some surgeons discuss a short drug holiday with your prescribing physician, though the evidence supporting the practice is weak. For denosumab (Prolia), stopping abruptly can trigger rebound vertebral fractures, so surgery is usually timed near the end of the six-month dosing window instead. The decision belongs to your physician and your surgeon together, not to either one alone.
MRONJ stands for medication-related osteonecrosis of the jaw — exposed jawbone that fails to heal after a dental procedure. For patients taking oral bisphosphonates at standard osteoporosis doses, the reported risk after invasive dental surgery is very low, commonly cited in the range of 0.02% to 0.1%. Risk rises with treatment duration beyond four years, with corticosteroid use, and dramatically with high-dose intravenous antiresorptives given for cancer.
Not necessarily. Grafting is driven by how much jawbone volume you have left after tooth loss, not by your DEXA T-score. Someone with severe osteoporosis who lost a tooth last month may need no graft at all, while someone with normal bone density who has worn a denture for fifteen years may need substantial reconstruction. A CBCT scan settles the question in a single appointment.
Many Las Vegas surgeons extend the osseointegration window from roughly three months to four to six months for patients with low bone density or softer Type III and IV bone, and they are more conservative about immediate loading. Total treatment time from surgery to final crown often runs five to eight months rather than three to four. The extra wait costs nothing and meaningfully improves long-term stability.
This article is general information, not medical or dental advice, and does not establish a doctor-patient relationship. Decisions about osteoporosis medication must be made with the physician who prescribed them. Cost figures are typical Las Vegas ranges and vary by practice and case complexity.
Find top-rated dental implant specialists across all Las Vegas neighborhoods — free consultations available.
Find a Specialist Near Me →